News|Articles|November 21, 2026

Beyond the Skin: How Inflammation Connects Dermatologic Disease

NP/PA Connect
Listen
0:00 / 0:00

Key Takeaways

  • Type 2 inflammatory signaling and barrier dysfunction can manifest across skin, lung, sinonasal, and esophageal tissues, warranting routine review of respiratory, nasal, and dysphagia symptoms.
  • Dupilumab exemplifies pathway-targeted therapy spanning multiple type 2 indications, potentially delivering steroid-sparing, multisystem control while remaining constrained by approvals, eligibility, and response heterogeneity.
SHOW MORE

DermNexus 2026 experts explored systemic inflammation, skin-gut connections, cancer risk, and multidisciplinary care in dermatologic disease.

Inflammatory skin diseases are increasingly recognized as conditions with implications extending beyond visible lesions. Shared immune pathways, overlapping comorbidities, and the systemic effects of chronic inflammation can complicate treatment decisions, underscoring the importance of evaluating patients beyond their dermatologic symptoms.

During "Rheum Connection Beyond the Skin: How Treating Inflammation Improves Comorbidities," the opening educational session of Day 2 at DermNexus 2026: The Inflammatory Disease and Innovations Congress for NP/PAs, held November 21 in Scottsdale, Arizona, Patricia M. Delgado, DNP, AGPCNP, DCNP, PMHNP; Kiranjit Khalsa, MD, MPH; Justin Moser, MD; and Sarabdeep Mann, MD, examined the connections between inflammatory skin diseases and systemic health.

The multidisciplinary discussion explored overlapping type 2 inflammatory pathways, gastrointestinal and metabolic comorbidities, skin cancer considerations, and the importance of patient-centered outcomes beyond visible skin clearance.

Throughout the session, faculty emphasized that effective management requires more than controlling cutaneous symptoms. Clinicians must also recognize systemic manifestations, coordinate care across specialties, and consider how treatment decisions influence patients' overall health and quality of life.

Shared Inflammatory Pathways Connect Skin and Airway Disease

The session began with an examination of the systemic effects of type 2 inflammation, particularly in patients with atopic dermatitis (AD) and other atopic conditions.

Faculty explained that inflammatory diseases involving the skin, lungs, nasal passages, and gastrointestinal tract may share underlying immune mechanisms, including epithelial barrier dysfunction and cytokine signaling.

"Inflammation does not stop with one organ," the presenting allergy specialist emphasized.

The discussion highlighted interleukin (IL)-4, IL-13, and IL-5 as important mediators of type 2 inflammation, contributing to disease manifestations across multiple organ systems.

For patients with AD, this may include coexisting asthma, allergic rhinitis, chronic rhinosinusitis with nasal polyps, or eosinophilic esophagitis (EoE).

Although patients may initially present with cutaneous symptoms, faculty encouraged clinicians to consider whether other manifestations of inflammation are contributing to their overall disease burden.

Chronic pruritus, sleep disruption, difficulty concentrating, and impaired daily functioning were identified as important consequences of inadequately controlled AD.

The presenter also encouraged clinicians to ask about respiratory symptoms, recurrent nasal problems, food-related concerns, and swallowing difficulties that may suggest additional conditions requiring evaluation.

Biologic Therapies and the Potential for Multisystem Benefits

The discussion then turned to the role of targeted biologic therapies in patients with overlapping inflammatory conditions.

Dupilumab, which inhibits IL-4 and IL-13 signaling through the IL-4 receptor alpha subunit, was highlighted as an example of a treatment with indications across multiple type 2 inflammatory diseases.

Faculty discussed its role in AD, selected patients with asthma, chronic rhinosinusitis with nasal polyps, EoE, and chronic spontaneous urticaria.

For patients with multiple qualifying conditions, selecting a treatment that addresses shared inflammatory pathways may provide benefits beyond improvement in skin symptoms alone.

However, the presenter emphasized that treatment decisions must remain grounded in disease-specific evidence, approved indications, eligibility criteria, and individual patient response.

The discussion also addressed the importance of reducing systemic corticosteroid exposure when appropriate.

Although corticosteroids can provide rapid relief during acute exacerbations, repeated or prolonged use may introduce additional risks, including metabolic complications, osteoporosis, hypertension, and infections.

Targeted biologics may offer steroid-sparing benefits in eligible patients, particularly when chronic inflammatory disease requires sustained control.

Faculty cautioned, however, that controlling existing atopic disease does not establish that biologic therapy prevents the development of future atopic conditions.

The Gut-Skin Connection in Psoriasis and Atopic Disease

The next presentation examined the relationship between inflammatory skin conditions and gastrointestinal disease, with particular attention to the gut microbiome and shared inflammatory pathways.

Faculty discussed how intestinal dysbiosis, altered immune signaling, and changes in intestinal permeability have been investigated as potential contributors to systemic inflammation.

Psoriasis, hidradenitis suppurativa, and inflammatory bowel disease (IBD) were highlighted as conditions with overlapping inflammatory mechanisms.

The presenter explained that although certain cytokine pathways contribute to both dermatologic and gastrointestinal inflammation, inhibiting a particular pathway may produce different effects depending on the affected organ.

IL-17 inhibition was discussed as an important example.

Although IL-17 inhibitors are effective treatments for psoriasis, this pathway also contributes to intestinal barrier function. In susceptible patients, IL-17 inhibition may exacerbate existing IBD or be associated with new gastrointestinal inflammatory symptoms.

Faculty encouraged clinicians to assess for relevant gastrointestinal symptoms and consider collaboration with gastroenterology when selecting systemic therapies.

The discussion also addressed the relationship between AD and EoE, which share type 2 inflammatory mechanisms involving IL-4 and IL-13.

For dermatology clinicians, recognizing symptoms such as dysphagia, food impaction, and food avoidance may help identify patients who warrant further gastrointestinal evaluation.

Recognizing Metabolic Liver Disease in Patients With Psoriasis

Another focus of the gastrointestinal discussion was metabolic dysfunction-associated steatotic liver disease (MASLD), previously referred to as nonalcoholic fatty liver disease.

Faculty described the association between psoriasis and metabolic liver disease, emphasizing the importance of considering metabolic comorbidities when evaluating patients with chronic inflammatory conditions.

The presentation reviewed how metabolic dysfunction can contribute to hepatic fat accumulation, inflammation, and progressive fibrosis.

In some patients, MASLD may progress to metabolic dysfunction-associated steatohepatitis (MASH), a more inflammatory form of liver disease.

The presenter encouraged dermatology clinicians to recognize patients who may benefit from further evaluation based on metabolic risk factors and relevant clinical findings.

This discussion reinforced the importance of considering cardiovascular and metabolic health alongside cutaneous disease activity when developing long-term management plans.

Balancing Skin Cancer Risk With Inflammatory Disease Control

The session also examined the complex relationship between chronic inflammatory disease, immunomodulatory treatments, and skin cancer risk.

A medical oncologist specializing in skin cancer management discussed how treatment decisions may become particularly challenging when patients require both inflammatory disease control and cancer treatment.

The presentation reviewed differences in skin cancer risk associated with various therapeutic approaches, including conventional immunosuppressants, biologics, and historical phototherapy regimens.

Faculty discussed the importance of cumulative treatment exposure, particularly with psoralen plus ultraviolet A (PUVA) phototherapy, when evaluating long-term risk.

The oncologist also addressed the challenges of treating patients with autoimmune conditions who develop advanced skin cancers.

Immune checkpoint inhibitors, which are used to treat certain skin cancers, can activate immune responses that may exacerbate underlying autoimmune disease.

Consequently, treatment decisions may require balancing the urgency of cancer management against the possibility of worsening inflammatory disease.

Clinical scenarios involving patients with longstanding psoriasis illustrated how previous treatment exposure, current disease control, and cancer severity may influence therapeutic decisions.

The presenter emphasized that these cases require close communication among dermatologists, oncologists, and other treating specialists rather than isolated decision-making.

Measuring Quality of Life Beyond Skin Clearance

The final presentation shifted attention toward patient-centered communication and the importance of measuring treatment outcomes beyond visible disease improvement.

A dermatology and psychiatric nurse practitioner discussed how chronic inflammatory skin diseases can affect sleep, mood, daily functioning, relationships, and overall quality of life.

The presentation also examined the relationship between chronic stress, neuroimmune signaling, and the itch-scratch cycle.

Faculty noted that persistent pruritus can involve changes in neural pathways associated with itch perception and reward, illustrating why chronic scratching should not be viewed simply as a behavioral issue.

The presenter emphasized that improvements in cutaneous symptoms do not necessarily resolve the psychological burden associated with chronic disease.

"Just because a patient's skin is clear doesn't necessarily mean that they're not going to be depressed anymore, that they're not going to be anxious anymore," the presenter said.

To better capture patient experiences, faculty discussed incorporating validated measures such as the Dermatology Life Quality Index (DLQI), along with screening tools for depression and anxiety.

These assessments may help clinicians evaluate changes in quality of life over time and identify concerns that might otherwise go unrecognized.

However, the presenter emphasized that questionnaires should complement, rather than replace, direct conversations with patients.

Asking patients what they hope to regain through treatment, whether improved sleep, greater confidence, or the ability to participate in daily activities, can help clinicians establish more meaningful therapeutic goals.

Advancing Multidisciplinary, Patient-Centered Care

The session concluded by reinforcing the importance of recognizing inflammatory skin diseases as part of a broader clinical picture.

Shared immune pathways can connect dermatologic conditions with respiratory, gastrointestinal, metabolic, and other systemic disorders, creating opportunities for coordinated treatment while introducing additional considerations for therapeutic selection.

Faculty emphasized that clinicians should evaluate comorbidities, assess medication risks, and collaborate with other specialties when necessary.

Equally important, treatment success should be measured through both clinical outcomes and patient-reported improvements in sleep, functioning, mental health, and quality of life.

As the management of inflammatory skin diseases becomes increasingly complex, the opening session of DermNexus 2026 Day 2 highlighted the importance of moving beyond skin clearance toward comprehensive, individualized care that addresses the full burden of disease.


Related to this article

Journal Digest: November 16
Recent dermatology research explores chronic hand eczema prevalence, cancer risk in morphea, pernio, biologic optimization in HS, and melanoma risk prediction.